Monte Rosa Therapeutics
Molecular-glue degrader company with a GSPT1 degrader in phase 2 for AR-mutant prostate cancer and a CCNE1-directed glue in preclinical development.
MRT-2359 (GSPT1) first patient dosed in phase 2 MODeFIRe-1 with apalutamide in AR-mutation-positive mCRPC (August 2026). AACR 2026: CCNE1-directed glue degrader produced regressions in CCNE1-amplified ovarian, breast, and gastric models with better selectivity than CDK2 inhibitors. QuEEN discovery engine; Novartis and Roche partnerships.
Pages like this
not linked directly; found by shared links- CompanyKymera Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, An open degrader consortium against every undruggable driver transcription factor, Design protein degraders small enough to get into the brain.
- CompanyC4 Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyNurix Therapeutics
Shares Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, Androgen receptor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaDestroy the truncated androgen receptor that hormone drugs cannot touch
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers, Prostate cancer.
- CompanyArvinas
Shares An open degrader consortium against every undruggable driver transcription factor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- PersonShaomeng Wang
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation).
- InstitutionUniversity Hospital Basel / Tumour Centre
Shares Novartis, Roche / Genentech, Ovarian cancer.